IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 5,570,000 shares, an increase of 98.2% from the April 30th total of 2,810,000 shares. Approximately 3.3% of the shares of the company are sold short. Based on an average daily volume of 2,150,000 shares, the days-to-cover ratio is presently 2.6 days.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock valued at $810,069,000 after purchasing an additional 312,807 shares during the last quarter. Geode Capital Management LLC lifted its holdings in IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after purchasing an additional 77,981 shares in the last quarter. Invesco Ltd. boosted its stake in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after buying an additional 798,534 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Price Performance

IQV traded down $0.86 during trading on Friday, hitting $140.16. The company's stock had a trading volume of 2,874,682 shares, compared to its average volume of 1,570,084. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $24.25 billion, a price-to-earnings ratio of 18.69, a P/E/G ratio of 1.99 and a beta of 1.34. The business's fifty day simple moving average is $150.79 and its 200 day simple moving average is $180.72. IQVIA has a twelve month low of $134.65 and a twelve month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.54 EPS. On average, equities research analysts forecast that IQVIA will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on IQV shares. Robert W. Baird reduced their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Finally, Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.